Smithkline Beecham Corporation

Glaxo Group Limited

Glazo Group Limited

Michael Anthony Forth

Francis Xavier Muller

Francis Dominic Sanderson

Susan ShuMei Hu Kopelman

Paul William Oxley

Michael B Mitchell

Kerry Joseph Gombatz

Jerome Francis Hayes

Darren Hewitt

Gary Francis Breen

Stephen Alexander Smith

Alan Collier

Paul Oxley

Disclosed is a novel polymorphic form of the compound of formula (I) also known as mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate, a process for the preparation of the polymorphic form, pharmaceutical compositions comprising the polymorphic form, and the use of the polymorphic form in medicine, particularly in antibacterial therapy.

Polymorph of mutilin

The present invention provides a novel process for preparing pleuromutilin derivatives, novel salts of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or solvates thereof, novel pharmaceutical compositions or formulations for topical administration comprising mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or a pharmaceutically acceptable salt or solvate thereof and their use in medical therapy, particularly antibacterial therapy.

Process, salts, composition and use

Process salts compositions and use

Processes and intermediates for the preparation of 2-substituted

Growing community of inventors

Tonbridge, United Kingdom

Michael Anthony Forth